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Background: The pathogenesis of obstructive sleep apnoea/hypopnoea syndrome (OSAHS), a highly prevalent
disease, is not completely understood. The purpose of this study was to investigate the contributions of Th17 cells
and the Th17-associated cytokines IL-17A and IL-17 F to OSAHS.
Methods: 46 male patients with a clinical suspicion of OSAHS were enrolled and divided into four groups based on
their polysomnography results: controls and mild, moderate, and severe OSAHS. The serum levels of IL-17A and IL-17 F
were determined by enzyme linked immunosorbent assay (ELISA), pulmonary arterial pressure (PAP) was determined
by echocardiography, and Th17 cell frequencies in peripheral blood were measured by flow cytometry.
Results: Serum IL-17A levels in the severe group were elevated (median value: control group 0.89 pg/ml, mild OSAHS
1.02 pg/ml, moderate OSAHS 1.18 pg/ml, and severe OSAHS 1.62 pg/ml; p < 0.05) and positively correlated with AHI
(r = 0.52, p < 0.05) but negatively related to the mean O2 saturation and lowest O2 saturation (r = −0.349, p < 0.05; and
r = −0.336, p < 0.05, respectively). Although the frequencies of Th17 cells in the OSAHS groups were higher than that in
the control group, these differences were not significant (p = 0.275). Pulmonary arterial hypertension was not present in
our patients as the median PAP of the normal control and the mild, moderate, and severe OSAHS groups were 26,
27.5, 24.5, and 25.5 mmHg, respectively (p = 0.676).
Conclusion: IL-17A may be involved in the pathogenesis of OSAHS and may represent a target for therapeutic
intervention.
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InflammationBackground
Obstructive sleep apnoea/hypopnoea syndrome (OSAHS)
is a breathing disorder that occurs during sleep. The
prevalence of OSAHS among adults is high, with esti-
mates of 3-7% of men and 2-5% of women [1]. The main
characteristics of OSAHS are repeated episodes of partial
or complete obstruction of the upper airway, which causes
markedly reduced (hypopnoea) or absent (apnoea) airflow,
and intermittent hypoxia and sleep deprivation that result
from these episodes of obstructed breathing. OSAHS
has been shown to be an independent risk factor for
cardiovascular and cerebrovascular diseases such as* Correspondence: lihequan@zju.edu.cn; zjyhz@zju.edu.cn
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heart failure, and stroke [2,3]. The mechanisms involved
in the associations between OSAHS and vascular diseases
are also complex. Animal and clinical data suggest that
intermittent hypoxia in OSAHS impairs endothelial func-
tion by altering the regulation of endothelial vasomotor
tone and repair capacity while promoting vascular inflam-
mation and oxidative stress [4].
Many immune system cell types, particularly T lympho-
cytes, participate in the pathogenesis of OSAHS. Dyugovs-
kaya and colleagues reported that the CD8+ T lymphocytes
from obstructive sleep apnoea patients undergo both
phenotypic and functional changes, rendering them cyto-
toxic to target cells such as vascular endothelial cells [5].
Recently, Tan et al. examined the populations of Th1,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with OSAHS and demonstrated that paediatric OSA is
associated with a reduced Treg population and a Th1/Th2
balance that is shifted toward Th1 predominance [6].
Th17 cells, a recently discovered subset of T helper cells
with a highly inflammatory nature, can secrete several
potent proinflammatory cytokines, including IL-17A and
IL-17 F, and are broadly implicated in inflammatory and
autoimmune diseases [7-9]. However, the pathological
effects of Th17 cells and their associated cytokines on
OSAHS have not been determined. Kobi Sade and col-
leagues demonstrated that decreased ratios of Th17/Treg
subpopulations may be involved in the pathogenesis of
adenoid hypertrophy [10], which is the main cause of
paediatric OSAHS [11]. In this study, we have explored the
contributions of Th17 cells and their associated cytokines,
IL-17A and IL-17 F, to OSAHS in adults.
Methods
Patients
Among the patients who visited our sleep disorders centre
with a clinical suspicion of OSAHS, 46 male patients were
enrolled in the study. All subjects underwent full-night
polysomnography (Artisan, Rembrandt, USA), and 37
patients were diagnosed as having OSAHS, with an
apnoea-hypopnoea index (AHI) > 5 (mild:AHI 5 ~ 15,
n = 10; moderate: AHI 15 ~ 30, n = 11; severe: AHI > 30,
n = 16). The AHI is the average number of apnoea and
hypopnoea episodes per hour of sleep. No patient had
previously been diagnosed with or treated for OSAHS.
All subjects were free of any acute or chronic infection,
cardiovascular diseases, and cancer and were taking no
medications. This study was approved by the Ethics
Committee of the First Affiliated Hospital of the Zhejiang
University School of Medicine, Zhejiang University. Writ-
ten informed consent was obtained from all subjects.
Polysomnography
The presence and severity of OSAHS were determined by
standard overnight polysomnography using electroenceph-
alogram (EEG), electrooculogram (EOG), electrocardio-
gram (ECG), chin electromyogram, and measurements
of oxygen saturation, airflow, and costal and abdominal
movements when breathing. Apnoea was defined as a ≥90%
decrease in airflow for at least 10 s relative to baseline.
Hypopnoea was defined as a ≥50% decrease in airflow
relative to baseline, with an associated ≥3% oxygen desat-
uration lasting at least 10 s [12]. As measured by AHI,
there were three levels of OSAHS: mild (5 ≤AHI < 15),
moderate (15 ≤AHI < 30), and severe (AHI ≥ 30).
Measurement of IL-17A and IL-17 F levels
Blood samples were obtained from the antecubital vein on
the morning after polysomnography and then centrifugedimmediately at 3,000 rpm for 10 min. Plasma samples
were stored at −80°C until use. The IL-17A and IL-17 F
levels were determined quantitatively using a platinum
enzyme-linked immunosorbent assay (eBioscience, San
Diego, CA). The minimum detectable doses of IL-17A
and IL-17 F were 0.23 pg/ml and 31.3 pg/ml, respectively,
and the intra-assay coefficient of variation was <10%.
Flow cytometry
Because we found a correlation between the serum level
of IL-17 and OSAHS, we conducted follow-up visits with
the study subjects to conduct additional research. How-
ever, only 17 subjects received a follow-up appointment
and participated further in our research.
Intracellular cytokines were studied by flow cytometry.
FITC-labelled anti-human CD4 (eBioscience) and PE-
labelled anti-human IL-17 (eBioscience) were used to
detect the Th17 cells. PBMCs, obtained from hepari-
nised peripheral whole blood (400 μl), were added to
1 ml of 1640 medium (PAA Laboratories, Pasching,
Austria) and incubated for 6 h at 37°C with 5% CO2 in
the presence of 50 ng/mL phorbol myristate acetate
(PMA) (BioVision, Mountain View, CA), 500 ng/mL
ionomycin (Fermentek, Jerusalem, Israel), and 1 μl of
GolgiPlug (eBioscience). The cells were then stained
with FITC-labelled anti-human CD4. After fixation and
permeabilisation, the cells were stained with PE-labelled
anti-human IL-17. Finally, the stained cells were analysed
by flow cytometry using a FACS Calibur (BD Biosciences),
and the results were analysed with CellQuest software
(BD Biosciences).
Measurement of pulmonary arterial pressure (PAP)
Doppler echocardiography, using Vivid 7 (GE Vingmed
Ultrasound, Horten, Norway) with a 2.5-MHz transducer
(Accuson Cypress, Siemens, Germany), was performed by
an experienced sonographer blinded to the study. The
peak velocity of the tricuspid regurgitation jet was used to
assess the PAP.
Statistical analysis
Statistical analysis was performed using SPSS statistical
software (SPSS, version 16.0 for Windows; SPSS Inc.,
Chicago, IL). The data were analysed using the Kruskal-
Wallis and Mann–Whitney tests. The Pearson test was
used to assess the correlation between variables. Differ-
ences were considered significant at p < 0.05.
Results
Demographic and sleep characteristics of subjects
A total of 46 male patients were analysed, with 37 in the
OSAHS group (AHI ≥ 5) and 9 in the control group
(AHI < 5). The characteristics of the study population
are shown in Table 1. The median ages of the normal
Table 1 Demographic and polysomnographic characteristics of the subjects (n = 46)
Control group (n = 9) Mild OSAHS (n = 10) Moderate OSAHS (n = 11) Severe OSAHS (n = 16) p value
Age (years) 50(22,63) 47.5(39,61) 42(30,65) 43.5(25,70) 0.823
BMI (kg/m2) 24.6(22,30.8) 26.9(22.6,30.8) 26(22.5,31.6) 29.4(23.7,38.4)* 0.029
AHI (events/h) 1.2(0.1,3.6) 8.6(5.7,15)* 26.2(15.1,30)*# 50.7(40.7,91.4)*△ 0.000
Lowest SaO2 (%) 91(86,95) 81(67,88)* 80(69,87)* 63(32,79)*#△ <0.001
Mean SaO2 (%) 97(96,98) 96(94,97) 96(94,98) 90.5(85,96)*#△ <0.001
The Kruskal-Wallis test was used to assess the differences among groups, and the Mann–Whitney test was used to test the significance of the differences between
two groups.
The data were summarised as median (minimum,maximum). * p < 0.05 versus control group; # p < 0.05 versus mild OSAHS group; △ p < 0.05 versus moderate OSAHS group.
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were 50, 47.5, 42, and 43.5 years, respectively (p = 0.823).
The median BMI was 26.9, 26,and 29.4 kg/m2 in the three
OSAHS groups, respectively, and 24.6 kg/m2 in the control
group (p = 0.029). In the severe group, the median oxygen
saturation (MSaO2) and lowest arterial oxygen saturation
(LSaO2) were significantly decreased compared with the
mild and moderate groups.
Elevated level of serum IL-17A is observed in patients
with OSAHS
The concentrations of IL-17A and IL-17 F were determined
by ELISA in our experiments. The median IL-17A level for
normal controls was 0.8 pg/ml, which was lower than that
for the OSAHS group. Moreover, the patients with more
severe OSAHS tended to have higher IL-17A levels; this
difference was significant (p < 0.001) (Figure 1A).
The serum level of IL-17 F in the OSAHS group was
higher than that in the normal group (p < 0.05). How-
ever, the differences among the OSAHS groups were not
significant (p > 0.05) (Figure 1B).
The concentration of IL-17A is related to the severity
of OSAHS
We found that the serum level of IL-17A in the OSAHS
groups was higher than that in the normal controlFigure 1 Serum level of IL-17A and IL-17 F were assessed by ELISA. T
versus control group; # p < 0.05 versus mild OSAHS group.group. Further regression analysis showed that the con-
centration of IL-17A was positively correlated with AHI
(r = 0.520, p < 0.01) (Figure 2) and negatively correlated
with LSaO2 (r = −0.336, p < 0.05) (Figure 3) and MSaO2
(r = −0.349, p < 0.05) (Figure 4).
The frequency of Th17 cells in peripheral blood has an
elevated trend in the OSAHS group
Among 46 patients, 17 patients did not receive any treat-
ment after diagnosis and were in the process of having
follow-up appointments. Table 2 lists each parameter.
The percentages of peripheral blood CD4+T lympho-
cytes that were also positive for intracellular IL-17 (i.e.,
Th17/CD4+ T cells) were determined for these patients
(Figure 5). The frequencies of Th17 cells in the OSAHS
groups trended higher compared with that in the control
group; however, the frequencies decreased with increasing
OSAHS severity. Overall, these differences were not
significant (p = 0.275).
PAH was not present in our patients
A resting mean pulmonary artery pressure (PAPm) >25
mmHg is the cut-off value for the diagnosis of manifest
pulmonary arterial hypertension (PAH), as set forth at
the 4th World Symposium on Pulmonary Hypertension
held at Dana Point in the United States in 2008 [13]. Inhe data are presented as median (minimum, maximum). * p < 0.05
Figure 2 The relationship between AHI and IL-17A level. There was a significant positive relationship between AHI and the IL-17A level
(r = 0.520, p < 0.01).
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in 17 patients. Our data did not support a diagnosis of
PAH in our patients as the median PAP of the normal
control and the mild, moderate, and severe OSAHS
groups was 26,27.5,24.5,and 25.5 mmHg, respectively
(p = 0.676) (Table 2).Figure 3 The relationship between LSaO2 and IL-17A level. There was
(r = −0.336, p < 0.05).Discussion
Redundant Th17 cells and their associated cytokines have
been shown to play a pathogenic role in autoimmune
diseases and chronic inflammatory diseases, and these
cells and cytokines may mediate many pathophysiological
processes that occur with hypoxia. To investigate thea significant negative relationship between LSaO2 and the IL-17A level
Figure 4 The relationship between MSaO2 and the IL-17A level. There was a significant negative relationship between MSaO2 and IL-17A
level (r = −0.349, p < 0.05).
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hypoxia, we measured the serum levels of IL-17A and IL-
17 F, PAP, and circulating Th17 cell frequencies in patients
with OSAHS.
OSAHS is a common chronic sleep disorder, the
pathogenesis of which is uncertain and likely to be a
multifactorial process that includes sympathetic excitation,
inflammation, and oxidative stress. Inflammation has been
confirmed to play a crucial role due to the occurrence
of recurrent hypoxia [14]. The unique form of hypoxia
present in OSAHS, with repetitive short cycles of desatur-
ation followed by rapid reoxygenation, termed intermittent
hypoxia, similar to ischemia-reperfusion injury, is associ-
ated with a series of inflammatory responses through
the induction of adhesion molecules and CRP in vascular
endothelial cells and leukocytes [15,16]. Numerous studies
have described an increase in the levels of systemicTable 2 Demographic and polysomnographic parameters, IL-
the subjects (n = 17)
Control group (n = 3) Mild OSAHS (n = 4)
Age (years) 50(37,61) 46(39,59)
BMI (kg/m2) 26.1(23.8,30.8) 26.1(24.8,30.4)
Lowest SaO2 (%) 89(86,90) 75(67,84)
Mean SaO2 (%) 96(96,96) 96.5(95,97)
AHI (events/h) 2.2(0.8,3.6) 6.5(5.7,15)
IL-17A (pg/ml) 0.07(0.02,0.14) 0.09(0.03,0.11)
Th17% 2.2(0.6,6.0) 8.5(4.3,9.5)
PAP (mmHg) 26(23,26) 27.5(23,30)biomarkers of inflammation, including CRP and IL-6,
in patients with OSAHS [17-19].
IL-6 is known to be an essential cytokine involved in
inducing the differentiation of Th17 cells in both humans
and mice. In the presence TGF-β, IL-6 activates the expres-
sion of the critical Th17 transcription factor RORC (RORγt
in mice) through the Jak/STAT3 pathway during Th17 cell
development [20,21]. In view of this role of IL-6, we
hypothesised that IL-17 levels may be elevated in patients
with OSAHS, and our results confirm this hypothesis.
Our study made several novel observations. First, the
serum levels of IL-17A, a proinflammatory cytokine, are
increased in patients with OSAHS; second, these elevated
levels of IL-17A are positively correlated with the severity
of OSAHS. Although there were significant differences in
the IL-17A concentrations, there was no significant differ-
ence in the Th17 ratios. The possible reasons for this lack17A concentrations, Th17 cell percentages, and PAP of









Figure 5 The percentage of CD4+IL-17+ cells. Single-cell suspensions prepared from the peripheral blood of 17 patients were double-stained
with FITC-conjugated anti-CD4 and PE-conjugated anti-IL-17 and were analysed by flow cytometry.
Ying et al. BMC Pulmonary Medicine 2014, 14:84 Page 6 of 7
http://www.biomedcentral.com/1471-2466/14/84of a difference in the Th17 frequency include limited sam-
ple size and the migration of Th17 cells. The first part of
our study involved 46 study subjects, and for the second
part of our study, we initially followed up with all of our
study subjects. However, some of our subjects had already
begun to receive treatment after their diagnosis, and such
treatment would have confounded our results. Thus, for
the second part of our study, we did not pursue patients
who had already begun treatment. We also lost additional
subjects to follow-up as a result of their unwillingness to
participate further in our study. Moreover, the complexity
and sensitive nature of flow cytometry makes the already
small ratio of Th17 cells difficult to measure accurately.
We have shown that adults with OSAHS are more likely
to exhibit an increase in circulating Th17 cells along with
elevated IL-17A levels. Th17 cells are able to promote the
activation, proliferation, and effector functions of a wide
range of immune system cells, in contrast to Treg cells.
Anderson and Tan recently described significant negative
correlations between the severity of paediatric OSA and
the percentage of Treg cells. An increase in the frequency
of Th17 cells, together with a reduction in the frequency
of Treg cells, could be a possible explanation for the link
between OSAHS and inflammation [6,22].
Some authors have reported that daytime PAH was
observed in severe OSAHS patients in the absence of
significant heart or lung disease [23,24]. Moreover, OSAHS
is frequently regarded as an independent risk factor for the
development of pulmonary hypertension, and the European
Respiratory Society (ERS) categorises OSAHS as a risk
factor for PAH [25]. The ERS hypothesises that one cru-
cial factor that may cause PAH in OSAHS is pulmonary
vasoconstriction, which is a direct response to alveolar
hypoxia and a cascade of biochemical and molecular
events that culminate in pulmonary vascular remodelling
[26,27]. However, PAH was not observed in our study,
and we did not find any link between the severity of
OSAHS and the level of PAP. The main reasons for thisdifference between the results of those studies and our
results may be the limited number of patients studied,
the length of illness, inter-individual differences in the
response to factors such as hypoxia and different meas-
urement methods for PAP.
There were also several limitations to our measure-
ments of patients’ PAP. First, we used transthoracic
echocardiographic indices to calculate PAP. Right heart
catheterisation is the gold standard for the diagnosis of
PAH [25]. However, the establishment of a definite diag-
nosis with this invasive method is always hampered by
several factors, including the risk to patients and patient
unwillingness to undergo to this procedure. Second, as a
result of loss to follow-up, only 17 patients had their
PAP measured.
Conclusions
Our data offered direct evidence that IL-17A is elevated
in patients with OSAHS and that the magnitude of this
increase is associated significantly with the severity of
OSAHS. As a pro-inflammatory cytokine, IL-17A may be
an important factor linking OSAHS to systemic inflamma-
tion. However, the clinical utility of the IL-17A assay for
the diagnosis of OSAHS and for the accurate evaluation
of severity still needs to be studied further. In addition,
large-scale, prospective studies are necessary to obtain
better knowledge of the relationship among Th17 cells,
PAP, and OSAHS.
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